Gouty arthritis: an approach for general practice

References

• Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8 Suppl 1:S1.
   PubMed Web of Science ®Google Scholar
• Ten Klooster PM, Vonkeman HE, van de Laar MAFJ. Disability due to gouty arthritis. Curr Opin Rheumatol. 2012;24(2):139–144.
   PubMed Web of Science ®Google Scholar
• Weaver AL. Epidemiology of gout. Clev Clin J Med. 2008;75 Suppl 5:S9–S12.
   PubMedGoogle Scholar
• Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12(6):223.
   PubMed Web of Science ®Google Scholar
• Smith EUR, Díaz-Torné C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24(6):811–827.
   PubMed Web of Science ®Google Scholar
• Schlesinger N, De Meulemeester, Pikhlak A, et al. Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat gouty arthritis by suppressing inflammation. Arthritis Res Ther. 2011;13(2):R53.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol. 2008;35(3):498–501.
   PubMed Web of Science ®Google Scholar
• Cassim B, Mody GM, Deenadayalu VK, et al. Gout in black South Africans: a clinical and gentic study. Ann Rheum Dis. 1994;53(11):759–762.
   PubMed Web of Science ®Google Scholar
• Mody GM, Naidoo PD. Gout in South African Blacks. Ann Rheum Dis. 1984;43(3):394–394.
   PubMed Web of Science ®Google Scholar
• Choi HK, Soriano LC, Zhang Y, García Rodríguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190.
   PubMed Web of Science ®Google Scholar
• McAdams DeMarco MA, Maynard JW, Baer AN, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities Cohort Study. Arthritis Rheum. 2012;64(1):121–129.
   PubMed Web of Science ®Google Scholar
• Wright AF, Rudan I, Hastie ND, Campbell H. A “complexity” of urate transporters. Kidney Int. 2010;78(5):446–452.
   PubMed Web of Science ®Google Scholar
• Choi HK, Gout B. Epidemiology, pathology, and pathogenesis. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. 13th ed. Atlanta, GA: Arthritis Foundation; 2008: p. 250–256.
   Google Scholar
• Terkeltaub R. Update on gout: new therapeutic strategies and options. Nature Rev Rheumatol. 2010;6(1):30–38.
   PubMed Web of Science ®Google Scholar
• Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82(3):421–426.
   PubMedGoogle Scholar
• Pascual E, Sivera F. Gout: new advances in the diagnosis and management of an old disease. Int J Clin Rheumatol. 2009;4:1–18.
   Google Scholar
• Edwards NL, Gout A. Clinical features. In: Klippel JH, Stone JH, Crofford LJ, White PH, editors. Primer on the rheumatic diseases. 13th ed. Atlanta, GA: Arthritis Foundation; 2008: p. 241–248.
   Google Scholar
• Pascual E, Sivera F, Andres M. Synovial fluid analysis for crystals. Curr Opin Rheum. 2011;23(2):161–169.
   PubMed Web of Science ®Google Scholar
• Janssens HJ, Fransen J, van de Lisdonk EH, et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Int Med. 2010;170(13):1120–1126.
   PubMed Web of Science ®Google Scholar
• Underwood M. Diagnosis and management of gout. BMJ. 2006,332(7553):1315–1319.
   Google Scholar
• Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301–1311.
   PubMed Web of Science ®Google Scholar
• Jordan KM. Up-to-date management of gout. Curr Opin Rheumatol. 2012;24(2):145–151.
   PubMed Web of Science ®Google Scholar
• Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46(8):1372–1374.
   PubMed Web of Science ®Google Scholar
• Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312–1324.
   PubMed Web of Science ®Google Scholar
• Gow P. Treating gout in patients with comorbidities. Int J Clin Rheumatol. 2011;6:625–633.
   Google Scholar
• Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. F1000: “Changes Clinical Practice”. Arthritis Rheum. 2010;62(4):1060–1068.
   PubMed Web of Science ®Google Scholar
• Choi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin in Rheumatol. 2010;22(2):165–172.
   PubMed Web of Science ®Google Scholar
• Gray CL, Walters-Smith NE. Febuxostat for treatment of chronic gout. Am J Health Syst Pharm. 2011;68(5):389–398.
   PubMed Web of Science ®Google Scholar
• Chohan S, Becker MA. Update on emerging urate-lowering therapies. Curr Opin Rheumatol. 2009;21(2):143–149.
   PubMed Web of Science ®Google Scholar
• Juraschek SP, Miller ER 3rd, Gelber AC. Effect of oral Vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res. 2011;63(9):1295–1306.
   Web of Science ®Google Scholar
• Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med. 2009;169(5):502–507.
   PubMedGoogle Scholar